Products

Edoxaban impurity C (hydrochloride) is an organic synthesis intermediate and pharmaceutical intermediate, which is mainly used in the laboratory organic synthesis process and the chemical and pharmaceutical research and development process, and can be used as a standard for impurity detection, mainly suitable for drug declaration and testing process.

The compound with CAS number 1210348-34-7 is an intermediate of edoxaban, an organic compound related to edoxaban, an oral anticoagulant used for the prevention and treatment of thrombosis-related diseases.
tert-Butyl[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate is a starting material and useful component of various drugs. It is mainly used as an organic synthesis intermediate and pharmaceutical intermediate, especially in the laboratory organic synthesis process and chemical and pharmaceutical research and development process, it can be used as a standard for impurity detection, and is suitable for drug declaration and testing process. In addition, it is also used in the synthesis of the anticoagulant edoxaban, including steps for amino-ester exchange, de-Boc protection/condensation of carboxylic acids and amines/salt formation, and hydrates.

The compound with CAS number 720720-96-7 is 5-methyl-4,5,6,7-tetrahydrothiazole[5,4-c]pyridine-2-carboxylate hydrochloride, also known as edoxaban impurity B (hydrochloride). This is an organic compound associated with edoxaban, an oral anticoagulant used to prevent and treat thrombosis-related diseases.

N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethyleneamide, toluene sulfonate is used in the preparation. It is a small molecule oral anticoagulant developed by Daiichi SansanChemicalbook Co., Ltd. in Japan, and is a coagulation factor X (FXa) inhibitor. During coagulation, activated coagulation factor X (FXa) activates prothrombin (FII) into thrombin (FIIa), which promotes fibrin formation, resulting in the formation of blood clots, making FXa a major target for the development of next-generation anticoagulant drugs.

The compound with CAS number 365998-36-3 is an edoxaban intermediate with the chemical name (5H-Pyrrolo[3,4-d]thiazole-5-carboxylic acid,2-[[[(1R,2S,5S)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl] cyclohexyl]amino]carbonyl]-4,6-dihydro-,1,1-dimethylethyl ester).This is an organic synthesis intermediate and pharmaceutical intermediate, which is mainly used in laboratory research and development processes and chemical and pharmaceutical synthesis processes, mainly as a synthetic intermediate of the API edoxaban. The intermediate has a solid powder, colorless or yellowish appearance, and is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and dichloromethane (DCM). In terms of synthesis method, edoxaban intermediates are prepared by reacting 5H-Pyrrolo[3,4-d]thiazole-5-carboxylic acid with an appropriate activator to form activated esters, then reacting with specific amines to form intermediate compounds, and finally introducing 1,1-dimethylethyl ester groups through esterification reactions.

Edoxaban impurity, chemically named N-(5-Chloropyridin-2-yl)oxalamic acid ethyl ester, is an organic compound.